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Abstract
Background: Keloids are an extreme form of abnormal scarring that result from a pathological fibroproliferative
wound healing process. The molecular mechanisms driving keloid pathology remain incompletely understood,
hindering development of targeted, effective therapies. Recent studies in our laboratory demonstrated that keloid
keratinocytes exhibit adhesion abnormalities and display a transcriptional signature reminiscent of cells undergoing
epithelial-mesenchymal transition (EMT), suggesting a role for EMT in keloid pathology. In the current study, we
further define the EMT-like phenotype of keloid scars and investigate regulation of EMT-related genes in keloid.
Methods: Primary keratinocytes from keloid scar and normal skin were cultured in the presence or absence of
transforming growth factor beta 1 (TGF-β1) +/− inhibitors of TGF-β1 and downstream signaling pathways. Gene
expression was measured using quantitative polymerase chain reaction. Migration was analyzed using an in vitro
wound healing assay. Proteins in keloid scar and normal skin sections were localized by immunohistochemistry.
Statistical analyses utilized SigmaPlot (SyStat Software, San Jose, CA) or SAS® (SAS Institute, Cary, NC).
Results: In keloid and normal keratinocytes, TGF-β1 regulated expression of EMT-related genes, including
hyaluronan synthase 2, vimentin, cadherin-11, wingless-type MMTV integration site family, member 5A, frizzled 7,
ADAM metallopeptidase domain 19, and interleukin-6. Inhibition of canonical TGF-β1 signaling in keloid keratinocytes
significantly inhibited expression of these genes, and TGF-β1 stimulation of normal keratinocytes increased their
expression. The inhibition of the extracellular signal-regulated kinase 1/2 (ERK1/2) signaling pathway or the p38
mitogen-activated protein kinase pathway attenuated TGF-β1-induced expression of subsets of these genes. Migration
of keloid keratinocytes, previously shown to be increased compared with normal keratinocytes, was significantly
reduced by inhibition of TGF-β1 or ERK1/2 signaling. Biomarkers of EMT, including reduced E-cadherin and increased
active β-catenin, were observed in keloid epidermis in vivo. However, evidence of basement membrane breakdown in
keloid scar was not observed.
Conclusions: The results suggest that keloid keratinocytes exist in an EMT-like metastable state, similar to
activated keratinocytes in healing wounds. The EMT-like gene expression pattern of keloid keratinocytes is
regulated by canonical and non-canonical TGF-β1 signaling pathways. Therefore, interventions targeting
TGF-β1-regulated EMT-like gene expression in keloid keratinocytes may serve to suppress keloid scarring.
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Background
Keloid scars are disfiguring fibrous growths that result
from an abnormal wound healing process in susceptible
individuals [1, 2]. Depending on their number, size, and
location, keloids can negatively impact quality of life and
disrupt activities of daily living [3]. Unlike hypertrophic
scars, keloids tend to increase in size indefinitely, spread-
ing beyond the original wound border although without
metastasis to distant sites. Keloid scars are responsible for
an estimated 427,000 physician visits per year in the USA;
however, the total number of affected individuals may be
greater because many people do not seek medical care [4].
The frequency of keloids is significantly higher in popu-
lations with darker skin pigmentation, such as African
Americans and Hispanics [4–6]. By the middle of this
century, the ethnic groups at greatest risk for keloid
scarring will make up over half of the US population
[7]. Therefore, keloids affect a large and increasing patient
population. Keloids are a difficult clinical problem because
they are refractory to treatment. Many therapies have low
to moderate response rates or are associated with high
rates of recurrence [1, 2]. High quality evidence is lack-
ing for most current keloid treatments, despite their
widespread use [8]. The underlying molecular pathology
of keloid scarring remains incompletely understood,
hindering development of more effective therapeutic
interventions [1].
Keloids are characterized by abnormal and excessive
deposition of extracellular matrix (ECM). Thus, fibro-
blasts have been the focus of the majority of keloid
research to date. However, it is well recognized that
keratinocytes are involved in regulation of fibroblast
activity during wound healing, and numerous recent
studies suggest that they have an important role in
abnormal scar formation. We previously described the
gene expression profile of keloid keratinocytes, which re-
vealed aberrant expression of numerous genes involved
in epithelial-mesenchymal transition (EMT), suggesting
involvement of EMT in keloid pathology [9]. In EMT,
epithelial cells lose their epithelial character, gain mes-
enchymal traits, and become less adhesive and more
migratory [10, 11]. Three types of EMT have been de-
scribed [12, 13]. Type I EMT occurs during embryonic
development to enable cells to take on different fates
during tissue morphogenesis and organ development.
Type II EMT occurs in the context of tissue injury as part
of the repair process, and is associated with inflammation.
Type III EMT occurs during cancer progression, enabling
epithelial-derived cancers to metastasize to distant
sites. EMT is considered a transient process that can be
reversed; for example, when metastatic cancer cells
form a secondary tumor at a new location. Type II
EMT ceases or reverses upon wound healing and reso-
lution of inflammation [11]. However, in the presence
of chronic inflammation, the repair process can be
prolonged, resulting in excess deposition of ECM and
formation of a fibrotic scar [14]. Thus, type II EMT has
been implicated in tissue fibrosis [11, 15]. In fibrotic
tissues, such as the kidney, it has been proposed that
type II EMT contributes directly to fibrosis by causing
epithelial cells to migrate locally through breaks in the
basement membrane into the mesenchymal compartment,
where they are reprogrammed to become ECM-producing
fibroblasts [16]. In vitro treatment of epithelial cells with
profibrotic cytokines can cause changes resembling EMT,
but whether this actually occurs in vivo has been some-
what controversial as it is difficult to document [17].
Although the three types of EMT represent distinct
and plastic physiological processes, they share a com-
mon set of phenotypic changes and are regulated by
similar sets of signaling pathways and effector mole-
cules [18]. Characteristic changes include alterations in
cell surface markers, including a switch from the epi-
thelial adhesion molecule E-cadherin (cadherin 1, type
1; CDH1) to N-cadherin (cadherin 2, type 1; CDH2) or
OB-cadherin (cadherin-11, type 2; CDH11); changes in
cytoskeletal proteins, including upregulation of the
mesenchymal marker vimentin; increased expression of
β-catenin, with decreased membrane localization and
increased cytoplasmic and nuclear levels; and changes
in transcription factors and basement membrane com-
ponents [10, 19]. A “core” set of genes that are up- or
downregulated during the EMT process has been iden-
tified, which includes genes involved in adhesion and
migration; development, differentiation, and prolifera-
tion; angiogenesis and wound healing; and metabolism
[20]. We found that many of these core EMT genes are
mis-expressed in keloid keratinocytes, suggesting that
EMT may have a central role in keloid pathology [9].
Compared with normal keratinocytes, keloid keratinocytes
exhibit reduced expression of genes involved in cell-cell
adhesion, altered expression of genes involved in epi-
dermal development and differentiation, and increased
expression of mesenchymal markers and biomarkers of
EMT. In vitro, keloid keratinocytes display increased
motility compared with normal keratinocytes. Keloid
scars in vivo exhibit adhesion defects, including abnor-
mal localization of desmosome components plakophilin
1 and junction plakoglobin (also known as γ-catenin), a
core EMT gene that encodes a component of adherens
junctions [9], and keloid scars were found to exhibit
ultrastructural alterations of the basement membrane
zone (BMZ) [21]. Recently, evidence of EMT in keloid
scar tissue was reported, including enhanced expression
of TGF-β1 and phosphorylated Smad3 [22]. However,
unlike type III EMT in cancer, which is associated with
basement membrane breakdown, keloid scars are not
known to metastasize to distant sites. Further, if type II
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EMT is occurring in keloid scars, the migration of kera-
tinocytes to the dermal compartment and their transi-
tion to mesenchymal cells has yet to be documented.
Understanding the pathways that control the EMT-like
gene expression profile of keloid keratinocytes, and
better defining the EMT-like characteristics of keloid
scars, may increase our understanding of the under-
lying pathology for development of improved, targeted
therapies.
Transforming growth factor β1 (TGF-β1) is a multi-
functional, profibrotic cytokine that is a major inducer
of all three types of EMT [13, 23]. In canonical TGF-
β1 signaling, binding of TGF-β1 to its receptors acti-
vates Smad2/3-dependent signaling; activated Smad2/3
complexes with Smad4 and translocates into the nu-
cleus to regulate expression of TGF-β-responsive genes
[12, 24]. During EMT, TGF-β1 signaling also occurs via
non-canonical, Smad-independent pathways. For example,
members of the mitogen-activated protein kinase (MAPK)
family, such as ERK1/2 and p38 MAPKs, have been impli-
cated in mediating many of the pathological activities of
TGF-β1, such as tumor cell metastasis [24]. TGF-β1 has
been shown to have a central role in keloid fibroblast
pathology [25]. TGF-β1 is overexpressed in keloid fibro-
blasts [26] and contributes to abnormal extracellular
matrix production in these cells [27]. TGF-β1 signaling
via both canonical and non-canonical pathways has been
implicated in abnormal gene expression in keloid fibro-
blasts [25, 28–30]. However, it is not clear whether TGF-
β1 is involved in regulating abnormal gene expression in
keloid keratinocytes. Treatment of normal epidermal kera-
tinocytes with TGF-β1 in vitro has been shown to induce
EMT biomarkers [31]. In mammary epithelial cells [32]
and corneal keratocytes [33], TGF-β1 is a potent inducer
of hyaluronan synthase 2 (HAS2), an enzyme involved in
hyaluronic acid biosynthesis that mediates EMT in these
cells. We previously reported that HAS2 is significantly
upregulated in keloid keratinocytes and contributes to
their enhanced motility in vitro [9, 34]. In the HaCaT
keratinocyte cell line, a line of spontaneously immortalized
human epidermal keratinocytes, TGF-β1-induced EMT
involved a set of genes that functions in cell-matrix adhe-
sion and migration [35]. Hypothetically, TGF-β1 may
regulate EMT-related abnormalities of keloid keratino-
cytes. The goal of the current study was to better under-
stand the putative role of EMT in keloid scarring, and to
determine the mechanisms that regulate EMT in keloid
keratinocytes.
Methods
Human tissue samples: ethics and consent
Keloid scar and normal skin samples were obtained
with approval of the University of Cincinnati Institutional
Review Board (IRB), in accordance with the Declaration of
Helsinki Principles, from patients at the Shriners Hospitals
for Children - Cincinnati and the University of Cincinnati
Medical Center (Table 1). Keloid scar samples were ob-
tained with written informed consent from patients
undergoing elective scar excision procedures. Written
consent was obtained from parents or legal guardians
of participants under the age of 18, with written assent
obtained from pediatric patients age 14 or over, prior to
sample collection. Patient information was anonymized,
and samples were de-identified prior to analysis. Collec-
tion of de-identified normal skin samples from plastic
surgery procedures was classified as “not human subjects
research” by the University of Cincinnati IRB and was
done without patient consent using discarded tissue.
Strain numbers were used to enable de-identification and
were assigned sequentially to all skin or scar samples
collected by the laboratory, including those used for this
study.
Primary cell culture
Primary keratinocyte cultures were established as de-
scribed elsewhere [9]. Briefly, tissue samples were cut
into 2–3 mm strips and were incubated in Dispase II
(Roche Applied Science, Indianapolis, IN) to separate
dermis from epidermis. Epidermal strips were treated
with 0.025 % trypsin (Sigma-Aldrich, St. Louis, MO),
Table 1 Demographic data for donors of keloid and normal skin
samples
Strain # Age (years) Gender Race Body site Scar
durationa
Keloid scar
746K 15 Male African American Face 8 yearsb
795K 20 Female African American Neck 2.5 yearsb
797K 10 Male White Ear 2 yearsb
821K 12 Male White Abdomen 2 years
823K 17 Male African American Ear 1.5 years
843K 16 Male White Face 1 year
860K 9 Female African American Face 3 years
874K 22 Male African American Back 3 yearsb
Normal skin
594 23 Male White Unknown NA
737 16 Female African American Breast NA
811 24 Female African American Breast NA
815 17 Female White Breast NA
877 17 Female African American Breast NA
879 12 Female White Thigh NA
880 15 Female White Breast NA
886 17 Male African American Abdomen NA
NA not applicable
aApproximate time in years since original injury or previous excision
bRecurrent scar
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followed by neutralization with 10 % fetal bovine serum
(Invitrogen/Thermo Fisher Scientific, Inc., Waltham,
MA) and filtration through Falcon® 70 μm cell strainers
(Corning, Inc., Corning, NY) to release keratinocytes,
which were inoculated into tissue culture flasks coated
with collagen (Coating Matrix; Invitrogen/Thermo Fisher
Scientific). Keratinocyte growth medium consisted of
MCDB 153 with 0.06 mM calcium chloride [36], supple-
mented with 0.2 % bovine pituitary extract (Hammond
Cell Tech, Windsor, CA), 1 ng/ml epidermal growth
factor (EGF; PeproTech, Rocky Hill, NJ), 5 μg/ml insu-
lin (Invitrogen/Thermo Fisher Scientific), 0.5 μg/ml
hydrocortisone (Sigma-Aldrich), and 1× Penicillin–
Streptomycin–Fungizone (Invitrogen/Thermo Fisher
Scientific). Cells were subcultured when they reached
80–90 % confluence onto tissue culture flasks without
collagen coating, using media as described above but
with 0.2 mM calcium chloride. At passage 2, cells were
harvested by trypsin treatment; 2 × 106 cells per strain
were used for isolation of RNA to compare gene ex-
pression in keloid and normal keratinocytes.
TGF-β1 and inhibitor treatments
To analyze the effects of inhibition of TGF-β1 signaling in
keloid keratinocytes, passage 3 cells of four donor strains
(746K, 795K, 797K, 823K; see Table 1) were inoculated
into six-well multiwell plates (Corning, Inc.) at 2000 cells/
cm2 in keratinocyte growth medium (described above).
After 48 h, the media was changed to keratinocyte growth
medium without EGF, with or without (vehicle only)
1.0 μM SB525334 (Selleck Chemicals, Houston, TX), and
cells were analyzed after 96 h. To analyze the effects of
TGF-β1 on normal keratinocyte gene expression, passage
3 cells of four normal donor strains (594, 811, 880,
and 886; see Table 1) were cultured in six-well plates
as described above, with or without (vehicle only)
1.0 ng/ml recombinant human TGF-β1 (PeproTech).
Media was refreshed after 48 h, and cells were lysed
for RNA isolation after 96 h. To analyze inhibition of
specific Smad-independent pathways downstream of
TGF-β1 signaling, inhibitors were tested in combin-
ation with TGF-β1. To inhibit extracellular signal-
regulated kinases 1 and 2 (ERK1/2) activation, cells were
treated with 10 μM U0126 (Cell Signaling Technology,
Danvers, MA), and for inhibition of p38 MAPK signal-
ing, cells were treated with 10 μM SB203580 (EMD
Millipore, Billerica, MA). At these concentrations,
U0126 and SB203580 have been shown to inhibit
ERK1/2 and p38 signaling, respectively, in normal hu-
man epidermal keratinocytes [37]. Keloid keratinocytes
from four donor strains (746K, 795K, 797K, 823K) were
inoculated at 25,000 cells/cm2 into six-well multiwell
plates; 24 h later, cells were pre-incubated with inhibi-
tors for 30 min prior to addition of 5 ng/ml TGF-β1.
Cells were harvested for analysis after 24 h. All experi-
ments were performed in duplicate for each strain
analyzed.
RNA isolation and gene expression analyses
Keratinocytes cultured in flasks (passage 2) were har-
vested by trypsin treatment and were pelleted prior to
RNA isolation. Keratinocytes cultured in multiwell
dishes (passage 3) were lysed without trypsin treatment.
Total RNA was purified using RNeasy Mini Kits (Qiagen
Inc., Valencia, CA). RNA samples were treated with
DNase I (Qiagen, Inc.) prior to synthesis of cDNA
using the SuperScript® VILO cDNA Synthesis Kit
(Invitrogen/Thermo Fisher Scientific). Quantitative
PCR (qPCR) was performed using gene-specific primers
(RT2 qPCR Primer Assays; Qiagen, Inc.), RT2 SYBR®
Green qPCR Mastermixes (Qiagen, Inc.) and the iCy-
cler iQ system (BioRad, Hercules, CA). Technical tripli-
cates were analyzed for each RNA sample, in addition
to biological replicates. Expression levels were refer-
enced to the glyceraldehyde 3-phosphate dehydrogen-
ase (GAPDH) gene using the comparative 2−ΔΔCt method
[38]. For comparison of mean expression levels in normal
and keloid keratinocytes (eight cell strains each), gene
expression levels were normalized to mean expression in
normal keratinocytes. For comparisons of mean expres-
sion levels in treated and untreated cells (four cell strains
per experiment), expression levels were normalized to
mean expression in untreated cells.
In vitro wound healing assay
Keloid keratinocytes from four donors (strains 746K,
795K, 797K, and 823K) were cultured to confluence in
six-well multiwell plates (Corning) coated with collagen
(Coating Matrix; Invitrogen/Thermo Fisher Scientific). At
time 0, media was changed to fresh growth media contain-
ing 10 μM U0126, 50 μM SB525334, or vehicle only
(controls), and wounds were created by scratching the
keratinocyte monolayer with a 200-μl pipet tip. Digital
photographs were taken using phase-contrast microscopy
at wounding and at 4, 8, 12, 16, and 24 h after wounding.
Three wells per strain were analyzed, and three micro-
scopic fields were photographed per well, for a total of
nine fields per cell strain per time point. The bottoms of
the wells were marked so that the same regions were
photographed in each well at each time point. Image ana-
lysis was used to calculate the open area of each micro-
scopic field (NIS-Elements AR3.1; Nikon, Melville, NY),
and these values were used to calculate percent closure.
Immunohistochemistry
Biopsies of keloid scar tissue or normal human skin were
embedded in Shandon™ M1 Embedding Matrix (Invitro-
gen/Thermo Scientific, Waltham, MA). Cryosections were
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fixed by incubation in methanol followed by acetone at
−20 °C. Immunohistochemistry was performed using
standard techniques. Primary antibodies included anti-
active-β-catenin mouse monoclonal antibody, clone 8E7
[39] (EMD Millipore, catalog #05-665), used at 1:100
dilution (16 h, 4 °C); anti-E-cadherin rabbit polyclonal
antibody (Abgent Inc., San Diego, CA, catalog #AJ1249a),
used at 1:500 dilution (1 h, room temperature); anti-
vimentin rabbit polyclonal antibody [40] (Abgent, Inc.,
catalog # AJ1815a), used at 1:500 dilution (1 h at room
temperature); anti-langerin mouse monoclonal antibody,
clone 12D6 [41] (LifeSpan BioSciences, Inc., Seattle, WA,
catalog #LS-C312086), used at 1:100 dilution (16 h, 4 °C);
anti-tyrosinase-related protein 1 (TYRP1) mouse mono-
clonal antibody, clone Ta99 [42] (BioLegend, San Diego,
CA, catalog #917801), used at 1:100 dilution (16 h, 4 °C);
anti-laminin 5 mouse monoclonal antibody, clone P3H9-2
[43] (Abcam Inc., Cambridge, MA, catalog #ab78286),
used at 1:500 dilution (1 h, room temperature); and anti-
integrin alpha 6 rat monoclonal antibody, clone GoH3
[44] (BD Biosciences, San Jose, CA, catalog #555734),
used at 1:100 dilution (1 h, room temperature). Labeled
secondary antibodies (all from Invitrogen/Thermo Fisher
Scientific) included Donkey anti-mouse IgG antibody,
Alexa Fluor® 488 conjugate (catalog #A21202); donkey
anti-mouse IgG antibody, Alexa Fluor® 594 conjugate
(catalog #A21203); chicken anti-rabbit IgG antibody,
Alexa Fluor® 488 conjugate (catalog #A21441); donkey
anti-rabbit IgG antibody, Alexa Fluor® 594 conjugate (cata-
log #A21207); goat anti-rat IgG antibody, Alexa Fluor® 594
conjugate (catalog #A21213); and donkey anti-rabbit IgG
antibody, Alexa Fluor® 350 conjugate (catalog #A10039).
Secondary antibodies were diluted 1:400 and incubated
with sections for 1 h at room temperature. Coverslips
were mounted on slides using Vectashield® Mounting
Media (Vector Laboratories, Burlingame, CA), with or
without 4,6-diamidino-2-phenylindole (DAPI) for coun-
terstaining of cell nuclei. Sections were viewed with an
Eclipse 90i microscope and photographed with a DS-Ri1
Digital Microscope Camera (Nikon Instruments Inc.,
Melville, NY).
Statistical analyses
For all experiments, keratinocytes from different do-
nors were cultured and analyzed independently; at no
point were cells of different donors combined in vitro.
Quantitative results are expressed as the mean (± standard
deviation) of values for individual cell strains. Statistical
analyses were performed using SigmaPlot for Windows
Version 11.0 (SyStat Software, Inc., San Jose, CA) or SAS®
Statistical Analysis Software (SAS Institute, Cary, NC).
Differences were considered statistically significant at p <
0.05. Pairwise comparisons of numeric values were ana-
lyzed by t test. Pairwise comparisons of categorical data
were analyzed using chi-square test. Comparisons in-
volving more than two values were done using one-way
analysis of variance (ANOVA) followed by multiple
pairwise comparisons using Tukey’s test. For the wound
healing assay, data were analyzed using a two-way ana-
lysis of variance with one repeated factor using the
MIXED procedure in SAS, and multiple comparisons
were done using the least squares means procedure
following statistical significance of the main effects.
Results
Cell donor characteristics
Primary keratinocytes were cultured from eight keloid
scars and eight normal full thickness skin samples col-
lected from 16 different individuals. Normal skin samples
were not collected from keloid scar patients for ethical
reasons, as biopsies of the non-lesional skin would result
in a high probability of new keloid scar formation in this
pediatric to young adult patient population. Tissue sam-
ples were from White or African American patients of
both genders, and from a variety of body sites (Table 1).
Keloid scar samples were from patients ranging in age
from 9 to 22 years (mean 15.13 ± 4.61 years), and normal
samples were from patients ranging in age from 12 to
24 years (mean 17.63 ± 4.00 years). Four of the keloids
were recurrent scars that returned following previous sur-
gical excision. Differences in age, gender, and race between
the keloid scar and normal skin donors were not statisti-
cally significant.
EMT-like gene expression in keratinocytes cultured from
keloid scars
Expression levels for seven genes implicated in EMT
were quantified in normal and keloid keratinocytes:
hyaluronan synthase 2 (HAS2); vimentin (VIM); cadherin-
11 (CDH11); wingless-type MMTV integration site family,
member 5A (WNT5A); frizzled 7 (FZD7); ADAM metallo-
peptidase domain 19 (ADAM19); and interleukin-6 (IL6).
These genes were selected for analysis because they were
identified in previous expression profiling studies to be
elevated in keloid keratinocytes compared with normal
keratinocytes [9], and they represent different types of
proteins previously shown in various contexts to be in-
volved in EMT. HAS2, VIM, CDH11, and WNT5A are
considered core EMT genes [20]. HAS2, among the most
highly upregulated genes in keloid vs. normal keratino-
cytes, is one of three HAS genes involved in synthesis of
hyaluronic acid. HAS2 overexpression was sufficient to
induce EMT in normal epithelial cells [45], and was dem-
onstrated to mediate TGF-β1-induced EMT in several
cancers [32, 46, 47]. VIM, an intermediate filament gene,
and CDH11, which encodes a component of adherens
junctions, are both considered markers of mesenchymal
cells that are increased during EMT [10, 19, 20, 48].
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WNT5A, a secreted signaling protein involved in canon-
ical and non-canonical WNT signaling, and FZD7, a re-
ceptor for WNT5A and other WNT proteins, are both
overexpressed in numerous cancers where they contrib-
ute to the EMT phenotype [49, 50]. ADAM19 is involved
in ectodomain shedding of cadherins, a proteolytic pro-
cessing event that contributes to reduced cadherin protein
levels during EMT [51, 52]. ADAM19 is overexpressed in
renal fibrosis where it is regulated by canonical TGF-β1
signaling [53]. IL6 is a proinflammatory cytokine that
induces expression of transcription factors involved in
EMT, increases VIM expression, and enhances cell motil-
ity [54, 55]. The mean expression levels for these seven
genes were higher in keloid keratinocytes than in normal
keratinocytes (Fig. 1a). However, the differences were only
statistically significant for HAS2, VIM, FZD7, and
ADAM19. This is likely due to the high degree of variabil-
ity in expression levels, particularly among keloid kerati-
nocytes isolated from different donors.
Regulation of EMT-like gene expression in keloid kerati-
nocytes by canonical TGF-β1 signaling
TGF-β1 has been shown to induce EMT via canonical
pathways, involving Smad signaling, and non-canonical,
Smad-independent pathways [23]. To determine if elevated
expression of EMT-related genes in keloid keratinocytes is
Fig. 1 Altered EMT-related gene expression in keloid keratinocytes is regulated by TGF-β1 signaling. (a, c, d) Gene expression was analyzed by
qPCR. Statistically significant differences are indicated by symbols: *p < 0.001; @p < 0.01; #p < 0.05. a A box plot was used to illustrate the variability
in gene expression, particularly among keloid scar keratinocytes. White bars represent expression levels in keloid keratinocytes, and gray bars represent
expression levels in normal keratinocytes. For each box, the box limits define the 75th percentile (upper) and 25th percentile (lower); the black bar
within the box indicates the median; the red bar within box indicates the mean; the whiskers represent the 90th percentile (upper) and 10th percentile
(lower); and circles represent outliers. b Experimental manipulation of TGF-β1 signaling in keloid and normal keratinocytes alters colony appearance in
vitro. Shown are representative images of keloid keratinocytes cultured in the absence (upper left) or presence (upper right) of SB525334 to inhibit TGF-
β1 signaling, and normal keratinocytes cultured in the absence (lower left) or presence (lower right) of TGF-β1. c Inhibition of TGF-β1 signaling in keloid
keratinocytes with SB525334 normalizes the EMT-like gene expression pattern. d Stimulation of normal keratinocytes with TGF-β1 induces expression
of genes involved in EMT
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regulated by canonical TGF-β1 signaling, cells were cul-
tured for 4 days in the presence of SB525334, a potent and
selective inhibitor of the TGFβ receptor I (activin receptor-
like kinase; ALK5). SB525334 inhibits ALK5 kinase activity,
and thereby inhibits TGF-β1-induced phosphorylation and
nuclear translocation of Smad2 and Smad3 [56]. Treat-
ment of keloid keratinocytes with SB525334 resulted in
changes in morphology that suggest alteration of adhesive
properties (Fig. 1b). Untreated keloid keratinocytes form
looser colonies compared with normal keratinocytes, and
appear more refractile under phase-contrast microscopy,
indicating a more rounded shape while growing on plastic.
Inhibition of TGF-β1 signaling by SB525334 treatment re-
sulted in more tightly associated colonies, and flatter, less
refractile cells, suggesting increased adhesive properties
(Fig. 1b). Analysis of Smad3 phosphorylation in these
cells (Additional File 1) is shown in Additional file 2: Figure
S1. Expression levels in keloid keratinocytes for EMT-
related genes HAS2, VIM, CDH11, WNT5A, FZD7,
ADAM19, and IL6 were significantly reduced by inhibition
of TGF-β1 signaling with SB525334 (Fig. 1c).
To determine whether TGF-β1 regulates expression
of the selected EMT-related genes in non-keloid cells,
normal epidermal keratinocytes were cultured for 4 days
with 1.0 ng/ml recombinant human TGF-β1. Compared
with untreated normal keratinocytes, which tend to
form tightly associated colonies in vitro, TGF-β1 treat-
ment of normal keratinocytes resulted in looser colonies
with greater separation among cells, a greater number of
elongated cells, and an increased number of refractile
cells, suggesting reduced adhesive properties, similar to
keloid keratinocytes (Fig. 1b). Expression levels for all
seven EMT-related genes were significantly increased in
normal keratinocytes by TGF-β1 treatment (Fig. 1d).
Involvement of non-canonical TGF-β1 signaling pathways
in EMT-like keloid keratinocyte gene expression
In addition to Smad-dependent signaling, TGF-β1 in-
duces EMT through parallel, Smad-independent path-
ways, including ERK1/2 and p38 [23, 24]. To begin to
investigate the role of non-Smad/MAP kinase pathways
in TGF-β1-induced EMT gene expression in keloid ker-
atinocytes, cells were pretreated with an inhibitor of
ERK1/2 signaling, U0126, prior to stimulation with
TGF-β1. For six of the seven genes tested—HAS2,VIM,
CDH11, WNT5A, ADAM19, and IL6—TGF-β1 stimula-
tion significantly increased expression in keloid kerati-
nocytes, as was observed in normal keratinocytes, and
this increase was significantly attenuated by inhibition
of the ERK1/2 pathway with U0126 (Fig. 2). For HAS2,
CDH11, ADAM19, and VIM, ERK1/2 inhibition also
significantly inhibited basal transcription levels, in the
absence of exogenous TGF-β1 (Fig. 2). Mean expression
levels for FZD7 were not significantly altered by either
TGF-β1 stimulation or U0126 treatment.
Previous studies demonstrated that treatment of normal
epidermal keratinocytes with the p38 inhibitor SB203580
attenuated the EMT-like phenotype induced by TGF-β1
[57]. To determine if p38 is involved in TGF-β1-regulated
EMT-like gene expression in keloid keratinocytes, cells
were cultured with or without TGF-β1 stimulation in
the absence or presence of SB203580. Pretreatment of
keloid keratinocytes with SB203580 significantly attenu-
ated TGF-β1-induced expression of HAS2, WNT5A, and
ADAM19, and basal expression of HAS2 was significantly
reduced by SB203580 treatment (Fig. 2). These results
suggest that p38 contributes to regulation of a subset of
EMT-related genes.
Inhibition of TGF-β1 signaling impairs migration of keloid
keratinocytes
Previous studies demonstrated that keloid keratinocytes
display increased migration rates compared with nor-
mal keratinocytes [9]. To investigate the role of TGF-
β1/Smad and ERK1/2 signaling in keloid keratinocyte
migration, an in vitro wound healing assay was per-
formed. Keloid keratinocytes were treated at the time of
wounding with either SB525334 or U0126. Both treat-
ments inhibited wound closure, with significant delays
compared with controls starting at 8 h after wounding
(Fig. 3). Interestingly, the kinetics of closure was slightly
different between the two treatment groups. Significant
differences between SB525334-treated and U0126-treated
keratinocytes were observed at 4 and 8 h after wounding,
with U0126-treated cells exhibiting higher migration rates
during this early period. No significant differences were
observed at 12 and 16 h after wounding, but by 24 h, mi-
gration of U0126-treated cells reached a plateau, and
wound closure at this time point was significantly lower
than in SB525334-treated cells (Fig. 3).
Biomarkers of EMT in keloid scar tissue
Immunohistochemistry was used to localize biomarkers
of EMT in keloid scar tissue. A previous study reported
features of EMT in keloid scar epidermis, including
increased levels of TGF-β1 and phosphorylated Smad3
compared to normal epidermis, and decreased E-cadherin
levels [22]. Decreased expression of E-cadherin, a compo-
nent of epithelial adherens junctions, is considered a hall-
mark of EMT [10]. We did not observe a statistically
significant difference in expression of the CDH1 gene,
which encodes E-cadherin, between normal and keloid
keratinocytes (data not shown). However, we observed
reductions in E-cadherin protein levels in keloid scars
compared with normal human skin biopsies (Fig. 4a–d).
The levels were variable among different scars samples
collected from different patients. Figure 4a–d illustrates
Hahn et al. Burns & Trauma  (2016) 4:30 Page 7 of 17
Fig. 2 Inhibition of ERK1/2 and p38 MAPK signaling in keloid keratinocytes alters TGF-β1-induced gene expression. Keloid keratinocytes (four donor
strains) were pre-incubated with inhibitors of ERK1/2 signaling (U0126) or p38 MAPK signaling (SB203580), prior to treatment with TGF-β1.
Gene expression levels, quantified by qPCR, are shown for HAS2 (a), VIM (b), CDH11 (c), WNT5A (d), ADAM19 (e), and IL6 (f). White bars, no treatment;
black bars, +TGF-β1; red bars, +U0126; yellow bars, +U0126 + TGF-β1; blue bars, +SB203580; green bars, +SB203580 + TGF-β1. Statistically significant
differences are indicated by symbols: *p < 0.001; @p < 0.01; #p < 0.05
Hahn et al. Burns & Trauma  (2016) 4:30 Page 8 of 17
the variable expression levels observed in two different
scars compared with two normal skin samples. Al-
though there was a trend towards reduced E-cadherin
levels in larger, more rapidly expanding keloids, there
were insufficient numbers of patients available to estab-
lish a statistically significant correlation between keloid
severity and E-cadherin expression (data not shown).
Interestingly, membrane localization of E-cadherin showed
a greater reduction in the upper epidermal layers, whereas
localization in normal epidermis was similar at all epider-
mal levels (Fig. 4A’–D’).
Another characteristic feature of EMT, increased levels
of cytoplasmic and nuclear β-catenin, was assessed in
keloid scar tissue. At the transcriptional level, we did not
detect significant differences in β-catenin expression
between keloid and normal keratinocytes, although β-
catenin expression was induced by TGF-β1 treatment of
keloid keratinocytes (Additional file 3: Figure S2). To
examine protein localization, immunohistochemistry
was performed using an antibody to the active form of
β-catenin, which is dephosphorylated on Ser37 or Thr41
[58]. Active β-catenin was detected in keratinocytes in
the uppermost nucleated layers of the epidermis in both
keloid scar and normal epidermis (Fig. 4e–h). However,
a broader band of expression was observed in keloid
epidermis, with three to five cell layers showing positive
staining for active β-catenin, compared with only one to
two cell layers in normal skin. The epidermal regions
with the highest levels of active β-catenin staining in keloid
scars corresponded to the regions with the lowest E-
cadherin levels (Fig. 4g).
As described above, expression levels of the mesenchy-
mal cell marker VIM were significantly higher in keloid vs.
normal keratinocytes in vitro. In keloid scar tissue, levels of
vimentin were higher in keloid epidermis compared with
normal epidermis (Fig. 4i, j), as was previously reported by
others [22]. In addition to positive intra-epidermal vimen-
tin staining, we observed vimentin-positive cells in the
basal epidermal layer (Fig. 4l). Interestingly, similarly local-
ized vimentin-positive cells were also observed in normal
epidermis (Fig. 4j).
Analysis of basement membrane integrity in keloid scars
Basement membrane breakdown is a critical step in
type I EMT during embryogenesis [59] and in adults type
III EMT in cancer during the progression to malignancy
[60, 61]. Transition of epithelial cells to fibroblasts that
transverse the basement membrane and migrate into the
mesenchyme is a feature of type II EMT that promotes
pathological fibrosis [61]. A previous report examined
vimentin expression in hypertrophic scars and found
vimentin-positive cells in proximity to the BMZ [62]. In
that study, partial breakdown of the basement mem-
brane was observed in proximity to epidermal cells ex-
pressing mesenchymal markers, suggesting EMT
accompanied by migration of cells from the epidermis
into the dermis [62]. Ultrastructural studies of keloid
scars previously showed abnormalities of the BMZ,
with decreased desmosome length and reduced hemi-
desmosome density in keloid scars compared with normal
skin [21]. The identification of increased vimentin
Fig. 3 Inhibition of TGF-β1 or ERK1/2 signaling inhibits migration of
keloid keratinocytes. a An in vitro wound healing assay was performed
to measure the effects of inhibitors of TGF-β1 signaling (SB525334) or
ERK1/2 signaling (U0126) on migration of keloid keratinocytes (N = 4
donor strains). Representative images of wound healing assay are
shown. b Quantitative analysis of the in vitro wound healing assay.
Mean values for four donor strains (+ standard deviations) are plotted
vs. time (hours). Statistically significant differences at specific time
points are indicated by symbols: *p < 0.001 control vs. both other
groups; $p < 0.001 control vs. SB525334; #p < 0.02 control vs. U0126;
@p < 0.05 SB525334 vs. U0126
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expression in keloid scars and localization of vimentin-
positive cells in the basal epidermal layer prompted us
to examine localization of basement membrane pro-
teins in keloids to investigate whether the locally inva-
sive behavior of keloid scars may involve EMT-related
breakdown of the basement membrane.
Laminin-332 (formerly known as laminin-5) secreted by
keratinocytes is a major component of the basement
membrane [63]. Laminin-332 interacts with other ECM
components, such as collagen type IV and collagen type
VII, and it complexes with integrin α6 to form a major
component of hemidesmosomes [63]. Discontinuities of
laminin-332 and integrin α6 BMZ staining were identified
in keloid epidermis, and the observed breaks in basement
membrane staining were associated with vimentin-positive
cells in the basal epidermal layer (Fig. 5a–c, g–i). Similar
vimentin-expressing cells were observed near the BMZ of
normal epidermis, adjacent to regions with apparent gaps
in laminin-332 or integrin α6 expression (Fig. 5d–f, j–l). In
both keloid scars and normal skin, positive staining
for integrin α6, which was previously reported to be
expressed in endothelial cells [64], was identified in
blood vessels and was co-localized with vimentin
(Fig. 5g–i). Localization of collagen IV, a type of collagen
expressed in the BMZ of the skin, showed linear expres-
sion at the dermal-epidermal junctions of both keloid
Fig. 4 Analysis of EMT biomarkers in normal human skin and keloid scar tissue. Immunohistochemistry was performed using antibodies against E-cadherin
(green; a-d, g-h), active β-catenin (red; e-h), and vimentin (red; i-j). Nuclei were counterstained with DAPI (blue) in all sections. Different keloid scar sections
are shown in left panels (a, c, e, g, and i). Normal skin sections are shown in right panels (b, d, f, h, and j). Panels a’–j’ are threefold magnified im-
ages of the boxed regions shown in a–j. (a–d) E-cadherin (green) is reduced in keloid scar epidermis (a, a’, c, c’) compared with normal epidermis (b,
b’, d, d’). Variable staining intensity is observed among keloids from different individuals, with relatively low levels in the upper dermal layers (as-
terisks in a’ and c’) compared with normal epidermis. (e–h) Regions of active β-catenin expression (red; indicated by arrowheads in e’–h’) are
increased in keloid epidermis (e, g) compared with normal epidermis (f, h). g, h E-cadherin and β-catenin show complementary expression pat-
terns in keloid epidermis. i, j Vimentin (red) is increased in keloid scar (i-i’) compared with normal skin (j-j’). Epidermal vimentin staining is observed in
cells of the basal layer (arrowheads) and within the upper epidermal layers (arrows). White scale bars (a–j), 100 μm; yellow scale bars (a’–j’), 50 μm. Repre-
sentative images are shown
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scars and normal skin, with no discernable differences or
breaks in staining (data not shown).
To better characterize the vimentin-positive cells in
keloid epidermis, immunohistochemistry was performed
using markers for different types of epidermal cells.
Vimentin-positive cells adjacent to breaks in laminin-332
staining at the basement membrane were negative for
keratin 15, a basal keratinocyte marker, suggesting they
are not keratinocytes (Fig. 6a–d), an observation con-
sistent with keratinocytes transitioning to mesenchymal
cells. However, closer examination of the intra-epidermal
vimentin-positive cells revealed a dendritic morphology,
suggesting that at least some of these cells may be
Langerhans cells, which were previously reported to ex-
press vimentin [65]. Colocalization of the Langerhans cell
marker, langerin, with some vimentin-positive cells in ke-
loid scar epidermis was observed, suggesting that many of
the vimentin-positive epidermal cells in keloid scars are
Langerhans cells (Fig. 6e–h). Further, many of the
vimentin-positive cells located near the BMZ in keloid
scars, adjacent to gaps in integrin α6 staining, were posi-
tive for the melanocyte-specific protein tyrosinase-related
protein 1 (TYRP1), indicating these cells are melanocytes
(Fig. 6i–l).
Discussion
A limitation of many current treatments for keloid
scarring, such as intralesional corticosteroid injection,
surgical excision, and 5-fluorouracil, is that they treat
the symptom, not the disease. They do not correct the
underlying pathology, which is not yet fully understood,
and thus are associated with high rates of recurrence
[66]. Many of the currently available therapies target
fibroblast activity. Hypothetically, these interventions
may fail to provide long-term suppression of keloid fibro-
sis because other cell types, in addition to fibroblasts, are
driving keloid pathology.
Keratinocytes are critical regulators of fibroblast activity
during wound healing, and recent studies suggest that
the epidermis can play an active role in dermal fibrosis
Fig. 5 Localization of basement membrane components and vimentin in keloid scar tissue and normal skin. (a–f) Immunohistochemical
localization of laminin-332 (LAM; red) and vimentin (VIM; green) in keloid scar (a–c) and normal skin (d–f). g–l Localization of integrin α6 (ITGA6;
red) and vimentin (VIM; green) in keloid scar (g–i) and normal skin (j–l). A single section is shown in each row. Panels in the right column (c, f, i, l)
show merged images; inset images are twofold magnifications of boxed areas. Arrows indicate vimentin-positive cells in regions with apparent
gaps in basement membrane staining for laminin-332 or integrin α6. Arrowheads (g–l) indicate blood vessels displaying colocalization of integrin
α 6 and vimentin in keloid scar (g–i) and normal skin (j–l). All panels are shown at the same magnification; scale bar in panel a, 100 μm
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[67–70]. Defects in epidermal integrity can promote fi-
brosis indirectly by increasing inflammation, which leads
to profibrotic stimulation of fibroblasts, or directly by se-
cretion of paracrine factors that regulate fibroblast prolif-
eration and matrix production. Additionally, it has been
proposed that keratinocytes can directly contribute to fi-
brosis via the process of EMT [11]. Previous expression
profiling studies from our laboratory strongly suggested a
role for EMT in keloid pathology [9]. Here, we extend
those studies to show that multiple genes with varying
functions during EMT are upregulated in keloid keratino-
cytes, and that expression of these genes in both keloid
and normal cells is regulated by TGF-β1. Further, the in-
duction of EMT-related genes in keloid keratinocytes is at
least partially mediated by ERK1/2 signaling, as inhibition
of the ERK1/2 pathway attenuated the TGF-β1-stimulated
increase in gene expression. In a subset of these genes, in-
duction of expression by TGF-β1 was also partially medi-
ated by p38.
TGF-β1-regulated expression of HAS2 [32], VIM [71],
CDH11 [48], WNT5A [72], IL6 [73], and ADAM19 [74]
has been previously implicated in EMT and fibrosis. Al-
though FZD7 has been previously implicated in EMT
[50], the regulation of FZD7 by TGF-β1 signaling has not
been previously described. In the current study, FZD7
expression was induced in normal keratinocytes by TGF-
β1 treatment and was downregulated in keloid keratino-
cytes by inhibition of TGF-β1 signaling. These results
implicate TGF-β1 in regulation of FZD7 in keloid and
normal keratinocytes. However, in experiments performed
to analyze the effects of ERK1/2 and p38 inhibitors on
TGF-β1-induced gene expression, significant differences
in FZD7 expression were not observed. This apparent
discrepancy may be due to differences in the treatment
conditions (inoculation density, culture time, and/or
TGF-β1 concentration) used for these experiments. Al-
ternatively, exogenous TGF-β1 may be insufficient to
upregulate FZD7 expression in keloid keratinocytes,
Fig. 6 Characterization of vimentin-positive cells in keloid epidermis. Immunohistochemistry was performed to localize vimentin and markers for
basement membrane, basal keratinocytes, Langerhans cells, and melanocytes in keloid scar tissue. (a–d) Localization of laminin-332 (LAM; green,
a), keratin 15 (KRT15; red, b), and vimentin (VIM; blue, c), and merged image (d). Arrows indicate cells at gaps in basement membrane that are
negative for keratin 15 and positive for vimentin. (e–h) Localization in keloid epidermis of integrin α6 (ITGA6; red, e), langerin (LANG; green, f), and
vimentin (VIM; blue, g), and merged image showing colocalization (h). Arrows indicate examples of cells positive for both langerin and vimentin;
arrowhead indicates vimentin-positive, langerin-negative epidermal cell. (i–l) Localization in keloid scar of integrin α6 (ITGA6; red, i), tyrosinase-related
protein 1 (TYRP1; green, j), vimentin (blue, k), and merged image showing colocalization (l). A single section is shown in each row. Scale bar in a is same
for all sections, 50 μm
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which is already significantly elevated compared with
normal keratinocytes. Further, it is possible that non-
canonical ERK1/2 and p38 pathways are not involved in
TGF-β1-regulated expression of this gene in keloid
keratinocytes.
In addition to inducing upregulation of EMT-related
genes, treatment of normal epidermal keratinocytes with
TGF-β1 changed their in vitro appearance, resulting in
less tightly adhered colonies. The phenotype of keloid ker-
atinocytes in vitro, which is characterized by loose cell-cell
and cell-substrate attachment and increased motility, was
partially normalized by inhibition of TGF-β1 signaling.
Inhibition of canonical TGF-β1 signaling by SB525334
treatment significantly reduced keloid keratinocyte mi-
gration rates in vitro. Inhibition of ERK1/2 signaling
also inhibited migration of keloid keratinocytes, but
with different kinetics than inhibition of canonical
TGF-β1 signaling. Taken together, the results suggest
that the TGF-β1/Smad2/3 and ERK1/2 signaling pathways
regulate overlapping but partially distinct sets of genes to
regulate migration and adhesion in keloid keratinocytes.
Hypothetically, simultaneous inhibition of both canonical
and non-canonical pathways downstream of TGF-β1 may
result in additive effects, as observed in other fibrotic
disorders [75], although this was not addressed in the
current study.
Our previous studies identified adhesion abnormalities
in keloid scar epidermis in vivo, including reduced expres-
sion of junction plakoglobin and plakophilin 1 [9]. Re-
cently, Yan et al. reported additional evidence of EMT in
keloid scars, including loss of E-cadherin expression and
gain of mesenchymal markers vimentin and fibroblast-
specific protein 1 in keloid epidermis [22]. Although we
did not detect a significant difference in E-cadherin gene
expression between normal and keloid keratinocytes,
reduced levels of E-cadherin protein were observed in
keloid epidermis. The difference in mRNA vs. protein
expression levels is not surprising because cadherin
switching, a prototypical feature of EMT, is regulated at
both the transcriptional and post-transcriptional levels
[19]. In the current study, the reductions observed in
E-cadherin protein levels were variable among scars
from different individuals; however, we did not observe
any keloid scar tissue that completely lacked E-cadherin
expression. This contrasts with the dramatic reduction
in E-cadherin expression reported by Yan et al. [22].
The discrepant results may be due to differences in the
techniques used for immunohistochemistry or due to
differences in the patient populations used for each
study.
Elevated expression of active β-catenin in keloid epider-
mis was previously reported by Chua et al. [76]. In the
current study, we extend those results to show that active
β-catenin expression in keloid epidermis is increased in
epidermal cells in regions that exhibit reduced E-cadherin
expression. E-cadherin is the main binding partner of β-
catenin at the cell membrane. Together with α-catenin,
this complex mediates cell-cell adhesion and links the
actin cytoskeletons of neighboring cells. Reduction of E-
cadherin levels disrupts cell adhesion and results in release
of β-catenin from the membrane. Once dissociated from
E-cadherin, β-catenin can accumulate in the cytoplasm
and translocate to the nucleus to activate genes involved
in EMT [77].
Expression of vimentin in epithelial cells is a hallmark of
EMT, and the significantly elevated expression of VIM in
keloid keratinocytes suggests induction of EMT in vitro.
We observed elevated expression levels of vimentin in
keloid scars and increased frequency of vimentin-positive
epidermal cells, compared with normal skin. Yan et al.
recently reported observing increased vimentin expression
in keloid epidermis and in keloid microvessels [22].
Expression of vimentin in the vascular endothelium of
keloid tissue was previously suggested as evidence of
endothelial-to-mesenchymal transition, which, like EMT,
has been proposed to contribute to fibrosis [78]. We ob-
served localization of vimentin-positive cells in vessels
of both keloid scars and normal skin. This is likely due
to vimentin expression in endothelial cells, which has
been previously reported [64], rather than the result of
a pathological transition. In the current study, we ob-
served numerous vimentin-positive cells localized to
the BMZ in both keloid scars and normal skin in vivo,
in association with apparent gaps in the basement
membrane. Similar observations in hypertrophic scars
were considered evidence of EMT-induced migration of
cells across the BMZ [62]. However, in the current
study, many of the vimentin-positive epidermal cells,
particularly near the BMZ, were likely melanocytes or
Langerhans cells. The results suggest that use of vimentin
as a marker of EMT must be approached with caution, as
it can be expressed in many different cell types [10]. The
results also emphasize the importance of comparing
keloid scar tissue with normal skin as a control, as certain
phenotypes associated with EMT may also be present in
some normal tissue samples.
The apparent increase of cells coexpressing vimentin
and langerin in the suprabasal layers of keloid epidermis
suggests that keloid scars may contain elevated numbers
of Langerhans cells. Previous studies reported no differ-
ence in Langerhans cell density among keloids, non-keloid
scars, and normal skin [79]. Although a large number of
scars were included in that study, the ages of the patients
and scar durations were not reported. In the current
study, scars of varying duration were investigated, includ-
ing active scars from relatively young patients, which may
have influenced the levels of Langerhans cells. Confirm-
ation of increased Langerhans cell density will require
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careful control of variables such as patient age, scar size,
and scar duration in subsequent studies.
Although ultrastructural alterations of desmosomes and
hemidesmosomes in keloid scars have been reported, we
did not find evidence of significant disruptions of the
epidermal-dermal BMZ in keloid scars. The apparent gaps
in laminin-332 and integrin α6 basement membrane stain-
ing were likely due to the absence of detectable expression
of these proteins in melanocytes and Langerhans cells in
the BMZ. Discontinuities of collagen IV localization in the
BMZ were not observed. EMT-associated basement mem-
brane breakdown is considered an important step during
tumor invasion and metastasis, enabling tumor cell de-
tachment, migration, and dissemination to distant sites
[60]. Although keloids are characterized by local spread
beyond the original wound boundary, metastasis to distant
sites does not occur. The lack of basement membrane
breakdown in keloid scars may be a key factor that pre-
vents metastatic spread of keloid scars.
Conclusions
The observation that keloid scars exhibit many of the
hallmarks of EMT, although failed to exhibit others,
suggests a role for partial EMT in keloid scarring. A
similar phenomenon was recently described in the
epidermis of patients with systemic sclerosis, a fibrotic
disease affecting the skin and other organs [80]. The
simultaneous expression of both epithelial and mesenchy-
mal traits has been referred to as a metastable state, which
represents an intermediate stage of EMT [81, 82]. The
metastable state is considered reversible upon removal of
the EMT stimulus, compared with the “epigenetically
fixed” state of complete EMT with transition to a mesen-
chymal phenotype [82]. The phenotype of activated kerati-
nocytes during wound re-epithelialization has been
considered a metastable state [83]. During wound healing,
keratinocytes exhibit morphological changes, display re-
ductions in numbers of cell-cell junctions, and become
migratory, similar to cells undergoing EMT. In normal
healing, this EMT-like metastable state is reversible; once
re-epithelialization is complete, keratinocytes revert to a
fully epithelial phenotype and re-establish stable cell-cell
and cell-substrate contacts. The present study suggests
that keloid keratinocytes are stalled in a metastable state,
regulated by canonical and non-canonical TGF-β1 signal-
ing pathways, which leads to pathological overhealing and
localized fibroproliferation.
We do not yet know the signals upstream of TGF-β1
that initiate the EMT-like changes of keloid keratinocytes
or fully understand the mechanisms that maintain their
metastable phenotype. Excessive inflammation, which has
long been thought to play a role in keloid pathology [84],
is also implicated in EMT [85]. Infiltrating immune cells
secrete cytokines that mediate EMT and support tumor
cell invasion and migration [85]. Hypothetically, in genet-
ically susceptible patients, excessive inflammation during
wound healing may tip the balance of canonical and non-
canonical TGF-β1 signaling, leading to an EMT-like state
that, in the absence of inhibitory signals, leads to patho-
logical overhealing. How the EMT-like state of keloid
keratinocytes contributes to keloid pathology remains to
be determined, but it has been previously shown that fac-
tors secreted by keloid keratinocytes can stimulate fibrotic
responses in fibroblasts [86]. In keloid scars, TGF-β1-
induced overexpression in keloid keratinocytes of secreted
factors, such as IL6 and WNT5A, may contribute to fibro-
sis directly, by stimulating signaling pathways in keloid fi-
broblasts that increase ECM production or indirectly by
promoting an inflammatory microenvironment [87–89].
Current keloid treatments that inhibit the activity of fibro-
blasts may fail to provide long-term suppression of fibrosis
if the EMT-like phenotype of keloid keratinocytes remains
unchecked. Therapeutic interventions that target the
EMT process to promote reversion to a stable epithelial
phenotype in keloid keratinocytes may be required, in
addition to treatments aimed at fibroblast activity, to fully
suppress keloid scarring.
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Additional file 1: Additional methods.
Additional file 2: Figure S1. Analysis of Smad3 phosphorylation in
normal and keloid keratinocytes treated with TGF-β1 or SB525334,
respectively. A. Western blot analysis of P-Smad3, Smad3, and β-actin
(loading control). Representative samples are shown: lane 1, normal
keratinocytes (untreated controls); lane 2, normal keratinocytes +
1.0 ng/ml TGF-β1; lane 3, keloid keratinocytes (untreated controls); lane
4, keloid keratinocytes + 1.0 μM SB525334. B. Quantitative analysis of
Smad3 phosphorylation in treated cells vs. controls.
Additional file 3: Figure S2. The gene encoding β-catenin is not
differentially expressed between normal and keloid keratinocytes, but
its expression is increased in keloid keratinocytes by TGF-β1. A. CTNNB1
expression in normal keratinocytes (NK; N = 8 strains) and keloid keratino-
cytes (KK; N = 8 strains) was determined by qPCR. No significant difference
was observed. B. Treatment of keloid keratinocytes with TGF-β1 resulted in
a significant increase in CTNNB1 expression. This increase was attenuated by
treatment with U0126 to inhibit ERK1/2 signaling, but not by inhibition of
p38 signaling with SB203580. Treatment with U0126 or SB203580 did not
affect basal CTNNB1 expression levels. Statistically significant differences are
indicated by symbols: *p < 0.001; #p < 0.05.
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